RTP Mobile Logo
Visiting Professors Gastrointestinal Cancer, Issue 1, 2014
Released August 2014

Featuring Drs Johanna C Bendell and Tanios Bekaii-Saab’s perspectives on their time spent visiting with patients with gastrointestinal cancer in the clinics of community oncologists. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    Colorectal cancer (CRC) is a common and potentially lethal type of cancer, and its clinical management is continuously evolving. Although “non-CRC” gastrointestinal (GI) tumors are less frequently encountered individually, the cancer-related deaths in that subcategory surpass those attributed to CRC. Published results from ongoing trials continuously lead to the emergence of novel biomarkers and new therapeutic targets and regimens, thereby altering existing management algorithms. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances.

    To provide clinicians with therapeutic strategies to address the disparate needs of patients with GI cancers, the Visiting Professors audio series employs an innovative case-based approach that unites the perspectives of leading GI oncology investigators and general oncologists as they explore the intricacies of making treatment decisions. Upon completion of this CME activity, medical oncologists should be able to formulate an up-to-date and more complete approach to the care of patients with GI cancers.

    LEARNING OBJECTIVES

    • Apply case-based learning, innovative communication strategies and shared clinical insight to provide comprehensive and compassionate oncology care for patients with GI cancer.
    • Develop evidence-based treatment approaches for patients diagnosed with HER2-positive metastatic gastric cancer.
    • Integrate the results of practice-changing clinical research into the selection and sequencing of chemobiologic regimens for patients with metastatic CRC.
    • Educate patients with metastatic gastric cancer or neuroendocrine tumors of the GI tract regarding approved and novel treatment approaches for unresectable disease.
    • Summarize key findings from clinical studies of emerging therapeutic regimens for pancreatic cancer, and use this information to guide treatment decision-making.
    • Communicate the benefits and risks of existing and emerging systemic interventions to patients with advanced hepatocellular carcinoma.
    • Counsel patients with early GI stromal tumors about the potential benefit of adjuvant imatinib, and define an evidence-based duration of treatment.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity contains an audio component. The participant should review the CME information and listen to the audio MP3s.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — Drs Bendell and Moriarty had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Bekaii-SaabConsulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech BioOncology, Lilly, Sanofi; Contracted Research: Oncolytics Biotech Inc, Pfizer Inc. Dr CartwrightAdvisory Committee: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Lilly; Speakers Bureau: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, AVEO Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Lilly, Novartis Pharmaceuticals Corporation and Onyx Pharmaceuticals Inc.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader (Optional)
    Sound card and speakers for audio

    Release date: August 2014
    Expiration date: August 2015

Acknowledge and close

Listen to audio:
Visiting Professors Gastrointestinal Cancer, Issue 1, 2014
Released August 2014

Featuring Drs Johanna C Bendell and Tanios Bekaii-Saab’s perspectives on their time spent visiting with patients with gastrointestinal cancer in the clinics of community oncologists. (Audio Content)

Read print: